Hims & Hers Faces Investor Deadline Following Partnership Collapse and Legal Challenges

Telehealth provider Hims & Hers Health, Inc. finds itself confronting significant legal challenges and a pressing deadline for shareholders. The company is the subject of multiple class action lawsuits, with investors who acquired its stock between April 29th and June 23rd, 2025, required to take action by Monday, August 25th. This date serves as the deadline to apply for the lead plaintiff position in the ongoing litigation.

The legal complaints allege that Hims & Hers and some of its executives violated the Securities Exchange Act of 1934. Central to the accusations are claims of misleading business statements concerning the company’s weight-loss medication segment. The lawsuits contend the firm engaged in “fraudulent advertising and the sale of illegitimate copycat versions of Wegovy®,” which allegedly “endangered patient safety.” Investors were purportedly kept in the dark regarding the risks associated with this GLP-1 drug business and a pivotal partnership.

Should investors sell immediately? Or is it worth buying Hims & Hers?

The situation reached a critical juncture on June 23rd, 2025, when Novo Nordisk publicly terminated its collaboration with Hims & Hers. The pharmaceutical giant explicitly cited “fraudulent practices” as the reason for the sudden dissolution of the partnership. The market’s reaction was severe and immediate. On the day of the announcement, the company’s share price plummeted by more than 34%, erasing over a third of its market value in a single session and severely damaging investor confidence.

This chain of events has placed considerable pressure on the company and its shareholders, who now face a narrow window to participate in the legal proceedings.